Article Text
Abstract
Introduction/Background Endometrial carcinoma (EC) is the most common gynaecological cancer in Europe and has an increasing incidence. The latest treatment guideline has integrated molecular profile into risk stratification, and emerging therapies are increasingly dependent on actionable biomarkers. Unfortunately, there is a lack of information on disease burden estimates that factor in a combination of prognostic factors, such as biomarkers, histology, stage and treatment history.
Methodology A flexible patient pathway framework was developed based on EC clinical practice guidelines and recommendations to assess disease burden by key biomarkers and other prognostic factors in 5 European countries: United Kingdom, Germany, France, Italy, Spain (EU5). Data pertaining to epidemiological outcomes and treatment utilization patterns was sourced from large cancer registry databases and the literature. Outcome measures were stratified by disease characteristics including biomarker, histology, stage and treatment history
Results An estimated 46,475 women would be diagnosed with EC in EU5 in 2020. Of these, 18,966 (40.8%) were estimated to be high-risk, 23,630 (50.8%) were non-high-risk, and 3879 (8.3%) were advanced metastatic when molecular classification was known. When p53 was not considered in the risk classification, only 32.4% patients were identified as high-risk vs 40.8%. Of the high-risk patients, an estimated 18,048 (95.2%) were expected to undergo surgery, of which 10,819 (59.9%) received adjuvant therapies and 6,434 had adjuvant chemotherapy with or without radiotherapy (RT) vs 4,385 had RT alone. Additionally, among all newly diagnosed EC patients, an estimated 27,278 (58.7%) patients would undergo 1L treatment, of which 13,061 (47.9%) had prior systemic therapy.
Conclusion Model estimates highlight the clinical burden of EC in patient sub-groups based on latest treatment guidelines, biomarkers and other prognostic factors across multiple countries in EU. This will help us understand burden better and help forecast treatment uptake patterns for novel therapies in EC more accurately.
Disclosures CM reports consulting fees from MSD, YL; KY; JL and RM are employees of MSD, GW, RH and CP are all employees of Adelphi Values PROVE™ who received consulting fees from MSD